

Innotive Diagnostics (InnotiveDx) Summary

InnotiveDx: Developing a Revolutionary Bacterial Infection (UTI) Diagnostic

InnotiveDx has engineered a novel, desktop, AI-enabled diagnostic system capable of precisely identifying the bacterial organism causing an infection and its antibiotic susceptibility within an unprecedented **60 minutes**, using a simple, single-use cartridge. This technology is a game-changer; no other solution currently offers such rapid and accurate diagnostics for *any* bacterial infection.

The global rise of **Antimicrobial Resistance (AMR)** is arguably the most pressing health crisis of our time. A major contributor to AMR is the current diagnostic paradigm for bacterial infections, including **Urinary Tract Infections (UTIs)**, and the critical lack of rapid tools for severe conditions like **Sepsis**. Current diagnostic methods are slow, often taking up to three days, are costly, and frequently inaccurate.

Technology Development So Far

InnotiveDx has made significant progress in bringing this groundbreaking technology to fruition. The company has already successfully developed a proprietary **single-use cartridge** prototype and a **laboratory suitable instrument (Pre-Alpha System)**. These components are currently undergoing rigorous testing with clinical samples. The company is well-protected by a robust IP portfolio, including six patents, valuable trade secrets, a proprietary bacterial image library, AI / Machine Learning algorithm, and specialized manufacturing expertise.

Further validating its innovative approach, InnotiveDx recently secured an almost **£1m PACE AMR grant** in collaboration with the prestigious **University of Oxford**. This significant grant underscores the scientific and clinical importance of InnotiveDx's work in addressing antimicrobial resistance.



Unparalleled Market Advantage & Validation

- **FDA Feedback:** InnotiveDx is uniquely positioned to meet the FDA's stringent requirement for all US tests to specify bacterial ID before AST results. No current competitor offers this crucial capability.
- **Exceptional Profit Potential:** With an expected cost of goods (COGS) below **\$5** and established US reimbursement codes for UTIs at **\$35+** and Sepsis at **\$105+**, InnotiveDx boasts a compelling high-profit margin.
- **Platform Technology for Sepsis:** Beyond UTIs, InnotiveDx's technology is a versatile platform with immense potential to revolutionize other bacterial infections diagnostics, e.g. sepsis.
- **Overwhelming Clinical Demand:** Feedback from clinics and doctors has been overwhelmingly positive:
 - **Prof. Ana Flores-Mireles, Notre Dame, USA** "Really impressive technology. It changes the POC diagnostics entirely with identification and AST in one test."
 - **Prof. Kalpana Gupta, Boston, USA** "Your UTI technology is brilliant! It reduces the downstream complications by early intervention and maximises public health impact."
 - **Prof. Patricia J Simner, Mayo Clinic, USA:** "This is a great solution to an overlooked problem. Providing ID and AST, separates you from any other technology."

Investment Opportunity

InnotiveDx is seeking equity investment of £10 million, to fund the optimisation and testing of its prototype diagnostic system.